{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:44:01Z","timestamp":1756993441074},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00105-022-04982-x","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T14:03:50Z","timestamp":1651154630000},"page":"336-343","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Januskinaseinhibitoren in der Therapie der Alopecia areata"],"prefix":"10.1007","volume":"73","author":[{"given":"Inbar","family":"Kobal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Ramot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"issue":"3","key":"4982_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.31887\/DCNS.2006.8.3\/tban","volume":"8","author":"TA Ban","year":"2006","unstructured":"Ban\u00a0TA (2006) The role of serendipity in drug discovery. Dialogues Clin Neurosci 8(3):335\u2013344. https:\/\/doi.org\/10.31887\/DCNS.2006.8.3\/tban","journal-title":"Dialogues Clin Neurosci"},{"issue":"4","key":"4982_CR2","first-page":"550","volume":"41","author":"L Drake","year":"1999","unstructured":"Drake\u00a0L, Hordinsky\u00a0M, Fiedler\u00a0V et\u00a0al (1999) The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J\u00a0Am Acad Dermatol 41(4):550\u2013554","journal-title":"J Am Acad Dermatol"},{"issue":"25","key":"4982_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/nejm198012183032516","volume":"303","author":"AR Zappacosta","year":"1980","unstructured":"Zappacosta\u00a0AR (1980) Reversal of baldness in patient receiving minoxidil for hypertension. N\u00a0Engl J Med 303(25):1480\u20131481. https:\/\/doi.org\/10.1056\/nejm198012183032516","journal-title":"N Engl J Med"},{"issue":"6","key":"4982_CR4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.ajo.2006.07.019","volume":"142","author":"M Centofanti","year":"2006","unstructured":"Centofanti\u00a0M, Oddone\u00a0F, Chimenti\u00a0S et\u00a0al (2006) Prevention of dermatologic side effects of bimatoprost 0.03\u202f% topical therapy. Am J Ophthalmol 142(6):1059\u20131060. https:\/\/doi.org\/10.1016\/j.ajo.2006.07.019","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"4982_CR5","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow\u00a0BG, King\u00a0BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a\u00a0patient with plaque psoriasis. J\u00a0Invest Dermatol 134(12):2988\u20132990. https:\/\/doi.org\/10.1038\/jid.2014.260","journal-title":"J Invest Dermatol"},{"issue":"4","key":"4982_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","volume":"2","author":"A Jabbari","year":"2015","unstructured":"Jabbari\u00a0A, Dai\u00a0Z, Xing\u00a0L et\u00a0al (2015) Reversal of alopecia areata following treatment with the JAK1\/2 Inhibitor baricitinib. EBioMedicine 2(4):351\u2013355. https:\/\/doi.org\/10.1016\/j.ebiom.2015.02.015","journal-title":"EBioMedicine"},{"issue":"5","key":"4982_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00403-018-1823-y","volume":"310","author":"Y Ramot","year":"2018","unstructured":"Ramot\u00a0Y, Marzani\u00a0B, Pinto\u00a0D et al (2018) IL-17 inhibition: is it the long-awaited savior for alopecia areata? Arch Dermatol Res 310(5):383\u2013390. https:\/\/doi.org\/10.1007\/s00403-018-1823-y","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"4982_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jdermsci.2015.01.004","volume":"78","author":"R Biran","year":"2015","unstructured":"Biran\u00a0R, Zlotogorski\u00a0A, Ramot\u00a0Y (2015) The genetics of alopecia areata: new approaches, new findings, new treatments. J\u00a0Dermatol Sci 78(1):11\u201320. https:\/\/doi.org\/10.1016\/j.jdermsci.2015.01.004","journal-title":"J Dermatol Sci"},{"issue":"9","key":"4982_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/exd.12209","volume":"22","author":"KJ McElwee","year":"2013","unstructured":"McElwee\u00a0KJ, Gilhar\u00a0A, Tobin\u00a0DJ et\u00a0al (2013) What causes alopecia areata? Exp Dermatol 22(9):609\u2013626. https:\/\/doi.org\/10.1111\/exd.12209","journal-title":"Exp Dermatol"},{"issue":"1-2","key":"4982_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000448379","volume":"2","author":"Y Ramot","year":"2016","unstructured":"Ramot\u00a0Y, Gural\u00a0A, Zlotogorski\u00a0A (2016) Alopecia areata as a\u00a0manifestation of systemic lymphoma: report of two cases. Skin Appendage Disord 2(1-2):63\u201366. https:\/\/doi.org\/10.1159\/000448379","journal-title":"Skin Appendage Disord"},{"issue":"4","key":"4982_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/0974-7753.130425","volume":"5","author":"Y Ramot","year":"2013","unstructured":"Ramot\u00a0Y, Molho-Pessach\u00a0V, Tenenbaum\u00a0A et al (2013) Alopecia areata and down syndrome: a\u00a0true association or a\u00a0coincidence. Int J Trichology 5(4):227\u2013228. https:\/\/doi.org\/10.4103\/0974-7753.130425","journal-title":"Int J Trichology"},{"issue":"2","key":"4982_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/0974-7753.77522","volume":"2","author":"Y Ramot","year":"2010","unstructured":"Ramot\u00a0Y, Thomaidou\u00a0E, Mali\u00a0A et\u00a0al (2010) An extraordinary colocalization of alopecia areata and vitiligo. Int J Trichology 2(2):108\u2013109. https:\/\/doi.org\/10.4103\/0974-7753.77522","journal-title":"Int J Trichology"},{"issue":"4","key":"4982_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/0974-7753.130397","volume":"5","author":"Y Ovcharenko","year":"2013","unstructured":"Ovcharenko\u00a0Y, Serbina\u00a0I, Zlotogorski\u00a0A et\u00a0al (2013) Renbok phenomenon in an alopecia areata patient with psoriasis. Int J Trichology 5(4):194\u2013195. https:\/\/doi.org\/10.4103\/0974-7753.130397","journal-title":"Int J Trichology"},{"issue":"4","key":"4982_CR14","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1111\/j.1440-0960.2011.00868.x","volume":"53","author":"Y Ramot","year":"2012","unstructured":"Ramot\u00a0Y, Sinclair\u00a0RD, Zlotogorski\u00a0A (2012) Regrowth of black hair in two red-haired alopecia areata patients. Australas J Dermatol 53(4):e91\u2013e92. https:\/\/doi.org\/10.1111\/j.1440-0960.2011.00868.x","journal-title":"Australas J Dermatol"},{"issue":"2","key":"4982_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaad.2015.09.045","volume":"74","author":"R Shreberk-Hassidim","year":"2016","unstructured":"Shreberk-Hassidim\u00a0R, Ramot\u00a0Y, Gilula\u00a0Z et al (2016) A systematic review of pulse steroid therapy for alopecia areata. J\u00a0Am Acad Dermatol 74(2):372\u2013374. https:\/\/doi.org\/10.1016\/j.jaad.2015.09.045","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4982_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","volume":"76","author":"R Shreberk-Hassidim","year":"2017","unstructured":"Shreberk-Hassidim\u00a0R, Ramot\u00a0Y, Zlotogorski\u00a0A (2017) Janus kinase inhibitors in dermatology: a systematic review. J\u00a0Am Acad Dermatol 76(4):745\u2013753e19. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.004","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4982_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/ced.12260","volume":"39","author":"Y Ramot","year":"2014","unstructured":"Ramot\u00a0Y, Tetro\u00a0T, Levi\u00a0I et al (2014) Remission of long-standing alopecia universalis after human immunodeficiency virus infection. Clin Exp Dermatol 39(3):399\u2013400. https:\/\/doi.org\/10.1111\/ced.12260","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"4982_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nm.3685","volume":"20","author":"SJ Divito","year":"2014","unstructured":"Divito\u00a0SJ, Kupper\u00a0TS (2014) Inhibiting Janus kinases to treat alopecia areata. Nat Med 20(9):989\u2013990. https:\/\/doi.org\/10.1038\/nm.3685","journal-title":"Nat Med"},{"issue":"5","key":"4982_CR19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1046\/j.1523-1747.1998.00380.x","volume":"111","author":"KJ McElwee","year":"1998","unstructured":"McElwee\u00a0KJ, Boggess\u00a0D, King\u00a0LE Jr et al (1998) Experimental induction of alopecia areata-like hair loss in C3H\/HeJ mice using full-thickness skin grafts. J\u00a0Invest Dermatol 111(5):797\u2013803. https:\/\/doi.org\/10.1046\/j.1523-1747.1998.00380.x","journal-title":"J Invest Dermatol"},{"issue":"9","key":"4982_CR20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing\u00a0L, Dai\u00a0Z, Jabbari\u00a0A et\u00a0al (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20(9):1043\u20131049. https:\/\/doi.org\/10.1038\/nm.3645","journal-title":"Nat Med"},{"issue":"15","key":"4982_CR21","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","volume":"1","author":"KM Crispin","year":"2016","unstructured":"Crispin\u00a0KM, Ko\u00a0JM, Craiglow\u00a0BG et\u00a0al (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 1(15):e89776. https:\/\/doi.org\/10.1172\/jci.insight.89776","journal-title":"JCI Insight"},{"issue":"7","key":"4982_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"A Jabbari","year":"2018","unstructured":"Jabbari\u00a0A, Sansaricq\u00a0F, Cerise\u00a0J et al (2018) An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J\u00a0Invest Dermatol 138(7):1539\u20131545. https:\/\/doi.org\/10.1016\/j.jid.2018.01.032","journal-title":"J Invest Dermatol"},{"issue":"1","key":"4982_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu\u00a0LY, Craiglow\u00a0BG, Dai\u00a0F et\u00a0al (2017) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90\u00a0patients. J\u00a0Am Acad Dermatol 76(1):22\u201328. https:\/\/doi.org\/10.1016\/j.jaad.2016.09.007","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4982_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","volume":"76","author":"BG Craiglow","year":"2017","unstructured":"Craiglow\u00a0BG, Liu\u00a0LY, King\u00a0BA (2017) Tofacitinib for the treatment of alopecia areata and variants in adolescents. J\u00a0Am Acad Dermatol 76(1):29\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2016.09.006","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"4982_CR25","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","volume":"153","author":"O Ibrahim","year":"2017","unstructured":"Ibrahim\u00a0O, Bayart\u00a0CB, Hogan\u00a0S et\u00a0al (2017) Treatment of alopecia areata with tofacitinib. JAMA Dermatol 153(6):600. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0001","journal-title":"JAMA Dermatol"},{"issue":"5","key":"4982_CR26","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2017.06.027","volume":"77","author":"H-S Park","year":"2017","unstructured":"Park\u00a0H\u2011S, Kim\u00a0MW, Lee\u00a0JS et al (2017) Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series. J\u00a0Am Acad Dermatol 77(5):978\u2013980. https:\/\/doi.org\/10.1016\/j.jaad.2017.06.027","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"4982_CR27","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1111\/jocd.13966","volume":"20","author":"DD Rota","year":"2021","unstructured":"Rota\u00a0DD, Emeksiz\u00a0MAC, Erdogan\u00a0FG et\u00a0al (2021) Experience with oral tofacitinib in severe alopecia areata with different clinical responses. J\u00a0Cosmet Dermatol 20(9):3026\u20133033. https:\/\/doi.org\/10.1111\/jocd.13966","journal-title":"J Cosmet Dermatol"},{"key":"4982_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13118","author":"N Akdogan","year":"2019","unstructured":"Akdogan\u00a0N, Ersoy-Evans\u00a0S, Do\u011fan\u00a0S et al (2019) Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.13118","journal-title":"Dermatol Ther"},{"issue":"4","key":"4982_CR29","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jaad.2018.12.041","volume":"80","author":"YX Dai","year":"2019","unstructured":"Dai\u00a0YX, Chen\u00a0CC (2019) Tofacitinib therapy for children with severe alopecia areata. J\u00a0Am Acad Dermatol 80(4):1164\u20131166. https:\/\/doi.org\/10.1016\/j.jaad.2018.12.041","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4982_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/pde.14422","volume":"38","author":"R Jerjen","year":"2020","unstructured":"Jerjen\u00a0R, Meah\u00a0N, Trindade de Carvalho\u00a0L et al (2020) Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study. Pediatr Dermatol 38(1):103\u2013108. https:\/\/doi.org\/10.1111\/pde.14422","journal-title":"Pediatr Dermatol"},{"issue":"15","key":"4982_CR31","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan\u00a0J, Jabbari\u00a0A, Nguyen et al (2016) Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight 1(15):e89790. https:\/\/doi.org\/10.1172\/jci.insight.89790","journal-title":"JCI Insight"},{"issue":"2","key":"4982_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000479722","volume":"4","author":"Y Ramot","year":"2018","unstructured":"Ramot\u00a0Y, Zlotogorski\u00a0A (2018) Complete regrowth of beard hair with ruxolitinib in an alopecia universalis patient. Skin Appendage Disord 4(2):122\u2013124. https:\/\/doi.org\/10.1159\/000479722","journal-title":"Skin Appendage Disord"},{"issue":"3","key":"4982_CR33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.33368","volume":"64","author":"Y Liu","year":"2012","unstructured":"Liu\u00a0Y, Ramot\u00a0Y, Torrelo\u00a0A et\u00a0al (2012) Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 64(3):895\u2013907. https:\/\/doi.org\/10.1002\/art.33368","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4982_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/DAD.0000000000000340","volume":"37","author":"A Torrelo","year":"2015","unstructured":"Torrelo\u00a0A, Colmenero\u00a0I, Requena\u00a0L et\u00a0al (2015) Histologic and immunohistochemical features of the skin lesions in CANDLE syndrome. Am J Dermatopathol 37(7):517\u2013522. https:\/\/doi.org\/10.1097\/DAD.0000000000000340","journal-title":"Am J Dermatopathol"},{"issue":"5","key":"4982_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1525-1470.2010.01163.x","volume":"28","author":"Y Ramot","year":"2011","unstructured":"Ramot\u00a0Y, Czarnowicki\u00a0T, Maly et\u00a0al (2011) Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome: a\u00a0case report. Pediatr Dermatol 28(5):538\u2013541. https:\/\/doi.org\/10.1111\/j.1525-1470.2010.01163.x","journal-title":"Pediatr Dermatol"},{"issue":"10","key":"4982_CR36","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jdcr.2019.07.005","volume":"5","author":"B Olamiju","year":"2019","unstructured":"Olamiju\u00a0B, Friedmann\u00a0A, King\u00a0B (2019) Treatment of severe alopecia areata with baricitinib. JAAD Case Rep 5(10):892\u2013894. https:\/\/doi.org\/10.1016\/j.jdcr.2019.07.005","journal-title":"JAAD Case Rep"},{"issue":"4","key":"4982_CR37","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","volume":"85","author":"B King","year":"2021","unstructured":"King\u00a0B, Ko\u00a0J, Forman\u00a0S et\u00a0al (2021) Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a\u00a0randomized controlled study. J\u00a0Am Acad Dermatol 85(4):847\u2013853. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.050","journal-title":"J Am Acad Dermatol"},{"key":"4982_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050","author":"B King","year":"2021","unstructured":"King\u00a0B, Guttman-Yassky\u00a0E, Peeva\u00a0E et al (2021) A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.050","journal-title":"J Am Acad Dermatol"},{"key":"4982_CR39","unstructured":"Research C. for D.E. (2021) FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Zugegriffen: 22.12.2021"},{"key":"4982_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.002","author":"S Chapman","year":"2021","unstructured":"Chapman\u00a0S, Kwa\u00a0M, Gold\u00a0LS et\u00a0al (2021) Janus kinase inhibitors in dermatology: Part I. A comprehensive review. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.002","journal-title":"J Am Acad Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-04982-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-022-04982-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-04982-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T09:04:36Z","timestamp":1652087076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-022-04982-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4982"],"URL":"https:\/\/doi.org\/10.1007\/s00105-022-04982-x","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"16 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Y.\u00a0Ramot hat Vortrags- und Beratungshonorare von Pfizer, AbbVie, Novartis und Lilly erhalten. I.\u00a0Kobal gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}